Professor Paul Workman, a seasoned medical researcher, lost his mother to chordoma, an untreatable rare bone cancer. Frustrated by the lack of treatment options for this condition, Workman's recent research focuses on the protein brachyury, vital for chordoma cell survival. This discovery suggests that targeting brachyury with specially designed drugs could lead to new treatments. Collaborating with colleagues from Oxford and North Carolina, Workman’s team utilized the Diamond Light Source synchrotron to explore brachyury's structure and identify potential drug targets, paving the way for innovative therapies against chordoma.
We will use the body's own defences to deal with brachyury. This breakthrough has allowed us to find specific target sites for drug development.
Thirty-six years ago, there was little we could do to treat chordoma. The recent discovery of brachyury gives us hope for effective treatment.
Our work using the Diamond Light Source synchrotron has enabled us to study brachyury in unprecedented detail, identifying potential drug targets.
Chordoma is a rare and untreatable cancer, affecting about one in a million people, but new research may open doors for effective therapies.
Collection
[
|
...
]